“Indeed, ketamine’s remarkable rapid, robust, and sustained antidepressant effects are considered to be ‘arguably the most important discovery in half a century’ for depression research” (Harvard Medical School) (Yale School of Medicine) 

“Our meta-analysis suggests that single administrations of ketamine are efficacious in the rapid treatment of unipolar and bipolar depression.” (Psychological Medicine) 

“A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression” (Journal of Affective Disorders) 

“Though convergence onto a specific brain area is elusive in depression, ketamine affects different areas of the brain in various ways, which may contribute to overall mood improvements.” (Harvard Medical School) 

“Blockade of NMDA receptors by ketamine increases the number and function of synapses” (Yale School of Medicine) 

“Ketamine-mediated synaptic plasticity changes appear to occur within a matter of hours after ketamine administration” (Mt. Sinai Hospital) 

“Ketamine infusion was associated with significant and rapid reduction in PTSD symptom severity, compared with midazolam” (Mount Sinai Hospital) 

“Ketamine, an NMDA receptor antagonist, has recently received attention as a possible novel pharmacologic agent for PTSD given the mounting evidence of its rapid antidepressant effects in mood disorders and its robust effect on neuroplasticity” (Yale School of Medicine) 

“Patients reported marked improvements in functionality and in their personal lives. Maintenance ketamine may be a therapeutic alternative for patients with treatment refractory Generalized and Social Anxiety Disorder” (Health Research Council of New Zealand) 

“Participants receiving ketamine first showed significant rapid reduction in obsessions during the infusion that persisted until 1-week post-infusion compared with participants receiving placebo first” (Columbia University) 

“A study of patients with anxious and non-anxious bipolar depression found that both anxious and non-anxious patients with bipolar depression had significant antidepressant responses to ketamine” (National Institute of Mental Health) 

“Our preliminary results suggest that IV ketamine is effective in rapidly treating anxiety irritability and suicidal ideation in adults with treatment-resistant mood disorders. This observation suggests that IV ketamine could be considered a treatment alternative for adults with Bipolar Disorder” (Bipolar Disorders Journal) 

“17 patients with migraine headache, significant improvements in pain were observed compared with placebo for acute pain (<1 hour) and for at least 15 days in 12 subjects following administration of subcutaneous ketamine” (International Journal of Clinical Pharmacology Research) 

“The simplest and most elegant explanation proposed for ketamine’s chronic pain–relieving properties is that it ‘resets the CNS,’ in essence reversing the deleterious effects of central sensitization by virtue of its NMDA-receptor antagonistic effects” (Journal of Chronic and Interventional Pain)